AstraZeneca Pharma India Ltd. - Research Center
506820 ASTRAZEN Group (A) BSE data
Add to watchlist
| Results |
Quarterly
|
| Statement | |
| More |
Quarterly results in brief
(Rs crore)
| Mar' 22 | Dec' 21 | Sep' 21 | Jun' 21 | Mar' 21 | |
|---|---|---|---|---|---|
| Sales | 231.96 | 200.53 | 197.71 | 175.40 | 210.26 |
| Operating profit | 37.96 | 14.67 | 17.92 | 15.63 | 40.41 |
| Interest | 0.21 | 0.23 | 0.25 | 0.27 | 0.28 |
| Gross profit | 41.44 | 19.77 | 20.51 | 18.26 | 42.68 |
| EPS (Rs) | 11.19 | 4.57 | 4.78 | 4.10 | 10.91 |
Quarterly
results in details
| Mar' 22 | Dec' 21 | Sep' 21 | Jun' 21 | Mar' 21 | |
|---|---|---|---|---|---|
| Other income | 3.68 | 5.33 | 2.84 | 2.90 | 2.55 |
| Stock adjustment | 3.07 | 12.46 | -16.79 | 15.73 | -6.70 |
| Raw material | 22.72 | 26.58 | 22.63 | 17.68 | 26.23 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 58.46 | 59.06 | 57.69 | 54.79 | 52.50 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | 14.46 | 9.84 | 10.28 | 10.15 |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 109.75 | 73.30 | 106.43 | 61.28 | 87.67 |
| Provisions made | - | - | - | - | - |
| Depreciation | 4.41 | 3.51 | 4.28 | 4.76 | 5.84 |
| Taxation | 9.05 | 4.85 | 4.29 | 3.26 | 9.56 |
| Net profit / loss | 27.98 | 11.42 | 11.95 | 10.24 | 27.28 |
| Extra ordinary item | - | - | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 16.36 | 7.31 | 9.06 | 8.91 | 19.22 |
| GPM (%) | 17.58 | 9.60 | 10.23 | 10.24 | 20.06 |
| NPM (%) | 11.88 | 5.55 | 5.96 | 5.74 | 12.82 |
Mutual Fund Selector
Find the fund that is right for you
© 2022 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis